Anne Chiang

Elevate Your Thoracic Oncology Practice 🫁 Don't just listen—participate. Join us in Covington, LA, on March 28, 2026, for an engaging and interactive experience at the Multidisciplinary Thoracic Tumor Board Conference. We’re moving beyond the standard lecture format to bring you: - Active dialogue with leading experts on the latest clinical breakthroughs. - Real-world case presentations analyzed through a collaborative tumor board lens. - Expert-led insights into 1st-line immunotherapy for advanced SCLC. - The opportunity to earn up to 5.25 CME | ABIM MOC Credits. Secure your spot for a day of high-impact learning and peer-to-peer collaboration. Register Now! - web.cvent.com/event/67b56a89… @Annechiangmd @PercyLeeMD @SurbhiSinghalMD @GavittWoodard @drgandara #Oncology #CME #LungCancer #MedicalConference #MTTB2026 #ThoracicOncology #MedicalEducation

As 2024 comes to a close, we would like to celebrate the advancements made in small cell lung cancer (#SCLC) that provide hope. This tremendous progress by clinical trials reflects the innumerable sacrifices made by such dedicated patients & their wonderful families. Thank you!

What a great NY Lung meeting! Great to see long-time friends as well as our lung fellows!

A busy week for Yale Thoracic Oncology @YaleCancer @YaleThoracic hosting a wonderful group of 🫁 oncologists, surgeons, and pulmonologists from Brazil. @oncoclinicas 🇧🇷 Great discussions, presentations, real and mock tumor boards. Look forward to ongoing collaboration!

@JournalCancer @OncoAlert @drshieldsmd @LaurenByersMD Amazing time for Sclc!!

🚀 #ASCO25 features a notable number of presentations spotlighting small cell lung cancer, signaling momentum in research, innovation & patient care. Stay in the know with the latest advances in #SCLC: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert @drshieldsmd @Annechiangmd @LaurenByersMD

Day 1 #SWOG: learning about AI in path for early stage breast cancer, mRNA lamellar aggregates and I-Checkit in Immunotherapeutics committee; ctDNA in CRC in translational plenary; stellar accrual to Pragmatica Lung and LungMap V3.0; so fun!

here’s how to register/check if you’re registered to vote!! Every vote counts! usa.gov/state-election…

@GavittWoodard @SmilowCancer @DrRoyHerbstYale @politikaterina Week 2 MDC- love the team approach to patient centered care!

Wednesday Yale thoracic multi-D clinic is the place to be! @SmilowCancer Having patients see a 🫁 surgeon and oncologist at the same time facilitates great care and a better patient experience! @DrRoyHerbstYale @Annechiangmd @politikaterina

@ILCC2024 @drgandara @DrRoyHerbstYale @fred_hirsch @HwakeleeMD

What a special meeting 25th ILCC Huntington Beach with fantastic colleagues and friends from all over to talk about the latest in lung cancer!! Thank you David, Heather, Roy for this opportunity!

.@AminNassarMD explores treatment options for 1st line treatment of advanced pure large cell neuroendocrine carcinoma #ASCO24 revealing similar outcomes for chemo, IO & chemoIO, questioning the added benefit of chemoIO compared to chemo alone @Annechiangmd @OncoAlert @SmilowCancer

Still on a high from #ASCO2024 and #ASCOLung- a surefire antidote to burnout! ⁦@RielyMD⁩ ⁦@LaurenByersMD⁩ ⁦⁦@HenryParkMD⁩ ⁦@JPatelMD⁩ ⁦@sands_jacob⁩

Loved catching up with old friends and making new ones at #ASCO24 @bjork5 @jmarinacevedo @sands_jacob @DasMillie11 @Annechiangmd @SalmaJabbour1 @JPatelMD #LCSM #SCLC

Closing ASCO 2024 with great discussions in this OncLive Peer Exchange on Immunotherapy in SCLC with updates from ASCO 2024 and recent advances with esteemed colleagues. Don’t miss it! @Annechiangmd @Tarita_ThomasMD Afshin Dowlati @OncLive

Reflecting on a banner day for SCLC patients with ADRIATIC @ #ASCO2024- a new standard of care and a huge step forward!! ⁦@DavidRSpigel⁩ ⁦@LaurenByersMD⁩ ⁦@SclcSMASHERS⁩

@Annechiangmd "we need to change our trials to fit the patient, not the other way around." She also spoke of sharing data from a study with a patient. Wow, how many of us have had an onc show us data? Informed patients can make better choices. #ASCO24

-Awesome discussion about advanced lung cancer by @MartinReck2 @Annechiangmd @MattGubensMD ! From IO, to SCLC, and non-EGFR actionable genomic aberrations! *Treatment selection for IO, chemo-IO, and dual-IO *SCLC is not “one size fits all”, this is 🔑 *NGS always! Tissue and 🩸

Thanks to Prof Anne Chiang and Prof Matthew Gubens for a fantastic educational session on NSCLC #ASCO24 @Annechiangmd @MattGubensMD

I’ll be speaking at PER’s symposia at the Annual Oncology Meeting May 31-June 2! Join me in Chicago: bit.ly/3wlrLq8 #gotoPER #ASCO24 @MLJohnsonMD2 @jmikhaelmd @HannyAlSamkari @LealTiciana

This drug tarlatamab really works and is a huge step forward for SCLC! Thanks to our patients!! ❤️ nytimes.com/2024/05/16/hea…